Kilitch Drugs (India) Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 26, 2025
KILITCH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kilitch Drugs (India) Limited held its 33rd Annual General Meeting on September 26, 2025 at 9:30 AM through video conferencing. All seven resolutions were approved by shareholders, with 99.99% of valid votes cast in favour of each resolution. Key items included adoption of audited financial statements for FY25, re-appointment of Mr. Bhavin Mehta as director, re-appointment of Mr. Mukund Mehta as Managing Director for another 5-year term, and continuation of Mr. Vasudev Krishna Murti as Independent Director. The promoters (holding 11,148,173 shares or ~63.8% of total equity) voted on most resolutions, except those in which they were deemed interested (re-appointment of Mukund Mehta and Bhavin Mehta, and waiver of PLI to executive directors). For those three resolutions, only public non-institutional shareholders (about 12.6 lakh votes, roughly 7.2% of total shares) participated.
Routine AGM outcome — all resolutions passed with overwhelming support. The re-appointment of Mukund Mehta as Managing Director for five years provides leadership continuity. Shareholders should note that promoters abstained from voting on resolutions involving their own interest, which is standard practice.